Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Covington
US Department of Justice
Cipla
Federal Trade Commission
Harvard Business School
QuintilesIMS
AstraZeneca
Healthtrust
Chubb

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 077483

« Back to Dashboard
NDA 077483 describes BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, which is a drug marketed by Mylan Pharms Inc, Sandoz, Actavis Labs Fl Inc, Ivax Sub Teva Pharms, Sun Pharm Inds Ltd, Mylan, and Apotex Inc, and is included in seven NDAs. It is available from eleven suppliers. Additional details are available on the BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE profile page.

The generic ingredient in BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is benazepril hydrochloride; hydrochlorothiazide. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the benazepril hydrochloride; hydrochlorothiazide profile page.

Summary for NDA: 077483

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 077483

Suppliers and Packaging for NDA: 077483

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
benazepril hydrochloride; hydrochlorothiazide
TABLET;ORAL 077483 ANDA Ranbaxy Pharmaceuticals Inc. 63304-154 63304-154-01 100 TABLET, COATED in 1 BOTTLE (63304-154-01)
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
benazepril hydrochloride; hydrochlorothiazide
TABLET;ORAL 077483 ANDA Ranbaxy Pharmaceuticals Inc. 63304-154 63304-154-10 1000 TABLET, COATED in 1 BOTTLE (63304-154-10)

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength5MG;6.25MG
Approval Date:Sep 8, 2005TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength10MG;12.5MG
Approval Date:Sep 8, 2005TE:RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength20MG;12.5MG
Approval Date:Sep 8, 2005TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
McKesson
Deloitte
US Department of Justice
AstraZeneca
Queensland Health
Healthtrust
Cantor Fitzgerald
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot